|Bid||0.00 x 12000|
|Ask||0.00 x 12000|
|Day's range||15.85 - 15.90|
|52-week range||15.31 - 49.99|
|Beta (5Y monthly)||1.61|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.80|
CAMBRIDGE, Mass., January 18, 2022--bluebird bio, Inc. (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for its lentiviral vector gene therapies – betibeglogene autotemcel (beti-cel) for β-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD). The revised PDUFA goal dates for beti-cel and eli-cel are August 19, 2022 and September 16, 2022, respectively.
CAMBRIDGE, Mass., January 11, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced planned updates to be presented at the 40th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook.
CAMBRIDGE, Mass., January 05, 2022--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40th Annual J.P. Morgan Healthcare Conference, Wednesday, January 12, at 3:45 p.m. ET.